News blog
Alliance Pharma
- BY: Andrew Hore |
- POSTED: 21/05/2009 |
Alliance Pharma says trading in the first four months of 2009 has been ahead of expectations.
Good news is becoming a habit for the pharmaceuticals supplier and that is why the shares have more than doubled in the past three months. Alliance is still on course to pay a maiden dividend.
Sales of Deltacortril, which is used for the treatment of inflammatory and auto-immune ailments, are rising and its profit contribution will be significantly higher than last year. Longer-term, this market may become more competitive.
At 11.5p a share, up 1.625p on the day, Alliance is valued at £18.6m.
Nigel Wray continues to build up his stake in Alliance. He added 2.7m shares during April giving him a 9.18% stake.
© 2024 Aim Micro. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Browse by issue
- All issues
- Popular tags
- All tags
- AIM Micro feeds
Keep up to date with articles published at AIMMicro.com. Subscribe to AIM Micro RSS Feeds
|